For example, genetically engineered exosomes displaying both anti-CD3 and anti-HER2 antibodies were able to dually target T-cell CD3 and breast cancer-associated HER2 receptors as a so-called T-cell engager to activate T cells against HER2 expressing tumor cells. This evidence concerns the gene ERBB2 and neoplasm.